OnKure Therapeutics (OKUR) Competitors $2.53 -0.14 (-5.24%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.44 -0.09 (-3.75%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OKUR vs. TARA, FTLF, ANEB, OKYO, CRDL, CRBP, CNTB, ALTS, TNYA, and ATOSShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Protara Therapeutics (TARA), FitLife Brands (FTLF), Anebulo Pharmaceuticals (ANEB), OKYO Pharma (OKYO), Cardiol Therapeutics (CRDL), Corbus Pharmaceuticals (CRBP), Connect Biopharma (CNTB), ALT5 Sigma (ALTS), Tenaya Therapeutics (TNYA), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry. OnKure Therapeutics vs. Its Competitors Protara Therapeutics FitLife Brands Anebulo Pharmaceuticals OKYO Pharma Cardiol Therapeutics Corbus Pharmaceuticals Connect Biopharma ALT5 Sigma Tenaya Therapeutics Atossa Genetics OnKure Therapeutics (NASDAQ:OKUR) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability. Does the media favor OKUR or TARA? In the previous week, OnKure Therapeutics had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 10 mentions for OnKure Therapeutics and 8 mentions for Protara Therapeutics. OnKure Therapeutics' average media sentiment score of 0.98 beat Protara Therapeutics' score of 0.84 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in OKUR or TARA? 91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts recommend OKUR or TARA? OnKure Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 1,178.00%. Protara Therapeutics has a consensus target price of $19.60, suggesting a potential upside of 546.86%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe OnKure Therapeutics is more favorable than Protara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is OKUR or TARA more profitable? Protara Therapeutics' return on equity of -36.87% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -60.52% -55.43% Protara Therapeutics N/A -36.87%-33.85% Which has more volatility and risk, OKUR or TARA? OnKure Therapeutics has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Which has higher valuation and earnings, OKUR or TARA? Protara Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$52.67M-$4.80-0.53Protara TherapeuticsN/AN/A-$44.60M-$1.62-1.87 SummaryOnKure Therapeutics and Protara Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.07M$3.10B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-0.5320.3830.5825.12Price / SalesN/A368.28464.36116.51Price / CashN/A42.3037.4059.05Price / Book0.448.659.096.18Net Income-$52.67M-$54.65M$3.25B$264.89M7 Day Performance24.02%6.58%7.42%4.22%1 Month Performance1.61%7.54%5.50%2.02%1 Year PerformanceN/A13.73%30.67%24.22% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics3.4422 of 5 stars$2.53-5.2%$32.33+1,178.0%N/A$36.07MN/A-0.53N/ANews CoverageEarnings ReportAnalyst RevisionGap DownTARAProtara Therapeutics2.1618 of 5 stars$3.16+3.3%$20.50+548.7%+47.8%$118.06MN/A-1.8430Earnings ReportAnalyst RevisionFTLFFitLife Brands4.1294 of 5 stars$13.05+4.4%$20.50+57.1%+6.5%$117.39M$64.47M15.5420News CoverageEarnings ReportAnalyst ForecastGap UpANEBAnebulo Pharmaceuticals2.2418 of 5 stars$2.70-5.3%$5.50+103.7%+28.9%$117.09MN/A-10.384Short Interest ↑Gap UpOKYOOKYO Pharma3.1509 of 5 stars$3.12+0.6%$7.00+124.4%+170.4%$116.59MN/A0.007Gap UpHigh Trading VolumeCRDLCardiol Therapeutics2.5472 of 5 stars$1.28-7.2%$8.00+525.0%-35.8%$114.09MN/A-3.7620News CoverageEarnings ReportGap UpHigh Trading VolumeCRBPCorbus Pharmaceuticals4.2935 of 5 stars$9.34+0.3%$49.38+428.6%-83.2%$113.92MN/A-2.2140CNTBConnect Biopharma3.304 of 5 stars$2.04+2.0%$7.00+243.1%+79.8%$111.12M$26.03M0.00110News CoverageAnalyst ForecastShort Interest ↓Analyst RevisionGap UpALTSALT5 Sigma0.6357 of 5 stars$6.81+8.4%N/A+228.2%$109.61M$12.53M0.00170News CoverageAnalyst DowngradeOptions VolumeTNYATenaya Therapeutics3.0349 of 5 stars$0.69+3.4%$6.25+801.5%-61.3%$109.08MN/A-0.60110ATOSAtossa Genetics2.8877 of 5 stars$0.83+1.3%$6.17+639.7%-39.3%$106.31MN/A-3.978Earnings ReportAnalyst Revision Related Companies and Tools Related Companies Protara Therapeutics Alternatives FitLife Brands Alternatives Anebulo Pharmaceuticals Alternatives OKYO Pharma Alternatives Cardiol Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Connect Biopharma Alternatives ALT5 Sigma Alternatives Tenaya Therapeutics Alternatives Atossa Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKUR) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access